

Table of Contents

1.	EXECUTIVE SUMMARY	5
1.1.	OPPORTUNITY	5
1.2.	CHALLENGES	5
1.3.	MANAGING SUCCESSFULLY IN THE U.S.	7
1.4.	SUMMARY	11
2.	INTRODUCTION	11
2.1.	OBJECTIVES	11
2.2.	THE SWISSMEDTECH® PROJECT	11
2.3.	MEDTECH SWITZERLAND	11
2.4.	ACKNOWLEDGEMENTS	12
3.	U.S. MEDICAL TECHNOLOGY INDUSTRY	13
3.1.	FACTS AND FIGURES	13
3.2.	U.S. PRODUCTION & CONSUMPTION OF MEDICAL DEVICES & DIAGNOSTIC PRODUCTS	15
3.3.	R&D SPENDING BY MEDICAL TECHNOLOGY COMPANIES	15
3.4.	M&A, VENTURE CAPITAL, AND IPO ACTIVITY IN THE MEDICAL TECHNOLOGY INDUSTRY	15
4.	U.S. HEALTHCARE INDUSTRY	17
4.1.	FACTS AND FIGURES	17
4.2.	THE NATIONS HEALTH DOLLAR	18
5.	CARDIOVASCULAR	23
5.1.	FACTS AND FIGURES	23
5.2.	MAJOR PLAYERS & MARKET SHARE ESTIMATES	27
5.3.	EMERGING TECHNOLOGIES	28
5.4.	MAJOR COMPETITORS IN THE CARDIOVASCULAR MARKET	32
6.	ORTHOPEDICS	34
6.1.	FACTS AND FIGURES	34
6.2.	MAJOR COMPETITORS IN THE ORTHOPEDIC DEVICES MARKET	43
6.3.	EMERGING TECHNOLOGIES	45
7.	DIAGNOSTICS	47
7.1.	FACTS AND FIGURES	47
7.2.	MAJOR COMPETITORS	51
7.3.	EMERGING TECHNOLOGIES	53
8.	MEDICAL IMAGING	55
8.1.	FACTS AND FIGURES	55
8.2.	MAJOR COMPETITORS IN THE U.S. MEDICAL IMAGING MARKET	57
8.3.	EMERGING TECHNOLOGIES	59
9.	REHABILITATION EQUIPMENT	61
9.1.	FACTS AND FIGURES	61
9.2.	MAJOR COMPETITORS	63
9.3.	LEADING CUSTOMER GROUPS	64
10.	DENTAL	66
10.1.	FACTS AND FIGURES	66
10.2.	MAJOR DENTAL MARKET PARTICIPANTS	70
10.3.	MARKET OUTLOOK AND INDUSTRY TRENDS	71
11.	DRUG-DEVICE COMBINATION PRODUCTS	72
11.1.	DEFINITION AND PRODUCT CATEGORIES	72
11.2.	FACTS AND FIGURES	73
11.3.	MAJOR PLAYERS	74
11.4.	CONVERGENCE STRATEGIES	76
11.5.	REGULATIONS	76
12.	MARKETING TOOLS AND DISTRIBUTION CHANNELS	77
12.1.	DEFINING DISTRIBUTION CHANNELS	77
12.2.	MARKET SEGMENTATION	77
12.3.	THE DECISION MAKERS	78
12.4.	PURCHASING PROCESS	79
12.5.	ROAD MAP FOR MARKET ENTRY	82
12.6.	IMPORTANCE OF OPINION LEADERS	82
12.7.	CLINICAL TRIALS	82
12.8.	PUBLICATIONS	84
12.9.	MARKETING PLATFORMS	85
12.10.	LEVEL OF PRESENCE	86
12.11.	AVERAGE MARGINS	87
12.12.	CONSIDERATIONS FOR MARKET ENTRY	87

13.	MARKETING AGREEMENTS, STRATEGIC PARTNERSHIPS AND LICENSING	88
13.1.	LEGAL ISSUES RELATED TO MARKETING IN THE UNITED STATES	88
13.2.	MARKETING ARRANGEMENTS	88
13.3.	MARKETING THROUGH A U.S. SUBSIDIARY OR BRANCH	88
13.4.	GENERAL CONTRACT ISSUES	89
13.5.	EXPLORING AND EVALUATING MARKET OPPORTUNITIES	89
13.6.	MARKETING AND LICENSING OF PRODUCTS AND KNOW-HOW IN THE UNITED STATES	90
13.7.	COOPERATION WITH U.S. COMPANIES	92
13.8.	ACQUISITION OR DISPOSITION OF U.S. COMPANIES OR ASSETS	92
<hr/>		
14.	REIMBURSEMENT	93
14.1.	OVERVIEW	93
14.2.	RELATIONSHIP OF PATIENTS, PROVIDERS, AND PAYERS	93
14.3.	REIMBURSEMENT	94
14.4.	ROLE OF INSURANCE	94
14.5.	PRIMARY TYPES OF PRIVATE INSURANCE COVERAGE	95
14.6.	TRENDS IN THE MANAGED CARE INDUSTRY	96
14.7.	MEDICARE AND MEDICAID	97
14.8.	COVERAGE DESCRIPTIONS	97
14.9.	LINKS TO OTHER SOURCES OF REIMBURSEMENT INFORMATION	97
14.10.	REIMBURSEMENT SPECIALIST COMPANIES	98
<hr/>		
15.	SUBCONTRACTING OPPORTUNITIES	99
15.1.	INTRODUCTION	99
15.2.	OUTSOURCING TRENDS	100
15.3.	CONSIDERATIONS BY OEMS IN CHOOSING AN OUTSOURCE PARTNER	100
15.4.	OUTSOURCING ARRANGEMENTS	101
15.5.	ACCESS TO U.S. CUSTOMERS	101
15.6.	FDA REGISTRATION OF SUBCONTRACTORS	101
15.7.	SUBCONTRACTING OPPORTUNITIES IN ORTHOPEDIC DEVICE MANUFACTURING	102
15.8.	U.S. MANUFACTURERS OF ORTHOPEDIC DEVICES	102
15.9.	IMPORTANT TRADE SHOWS AND PUBLICATIONS FOR ORTHOPEDIC DEVICE OEMS AND CONTRACT MANUFACTURERS	102
15.10.	SUBCONTRACTING OPPORTUNITIES IN CARDIOVASCULAR DEVICE MANUFACTURING	104
15.11.	IMPORTANT TRADE SHOWS AND PUBLICATIONS FOR CARDIOVASCULAR DEVICE OEMS AND CONTRACT MANUFACTURERS	104
15.12.	OEM/SUBCONTRACTOR COLLABORATION TRENDS IN REPROCESSING SINGLE USE DEVICES (SUDS)	105
15.13.	SUBCONTRACTING OPPORTUNITIES FOR DENTAL INSTRUMENTS	106
15.14.	SUBCONTRACTING OPPORTUNITIES IN MEDICAL ELECTRONICS	106
<hr/>		
16.	IMPORTING INTO THE UNITED STATES	107
16.1.	OVERVIEW	107
16.2.	U.S. CUSTOMS AND BORDER PROTECTION (CBP)	107
16.3.	THE ENTRY PROCESS	108
16.4.	CLASSIFICATION AND VALUATION OF IMPORTED PRODUCTS	109
16.5.	COUNTRY OF ORIGIN MARKING	110
16.6.	PENALTIES AND COMPLIANCE ISSUES	110
<hr/>		
17.	FDA: BRINGING A MEDICAL DEVICE TO MARKET: PREMARKET REVIEW	112
17.1.	INTRODUCTION	112
17.2.	PMA – 510(K) DISTINCTION	112
17.3.	PRODUCT STATUS	113
17.4.	MEDICAL DEVICE CLASSIFICATION	113
17.5.	PREMARKET NOTIFICATION PROCESS 510(K)	114
17.6.	PREMARKET APPROVAL	115
17.7.	SUMMARY	116
17.8.	CONCLUSION	116
<hr/>		
18.	PRODUCT LIABILITY LEGAL ASPECTS	116
18.1.	THE LEGAL BASIS FOR U.S. PRODUCT LIABILITY	117
18.2.	DAMAGES	118
18.3.	PROCEDURAL ASPECT OF A U.S. PRODUCT LIABILITY	118
18.4.	PRODUCT LIABILITY EXPOSURE THROUGH MERGERS/CONSOLIDATIONS AND ACQUISITIONS	122
18.5.	REDUCING THE RISK OF PRODUCT LIABILITY	123
<hr/>		
19.	ANNEXES	124
19.1.	ANNEX I: LINKS TO DATA SOURCES	124
19.2.	ANNEX II: TRADE ASSOCIATIONS, TRADE SHOWS, AND PUBLICATIONS	124
19.3.	ANNEX III - LIST OF MEDICAL ACADEMIES, SOCIETIES, AND OTHER PLATFORMS	129
19.4.	ANNEX IV: END NOTES	132
19.5.	ANNEX V: THE AUTHORS OF THE STUDY	136